Chee Khoon Lee

Abstract SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n = 114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines.

ADCs Antibody-Drug Conjugates AEs Adverse Events ALK Anaplastic Lymphoma Kinase ctDNA Circulating Tumour DNA EGFR Epidermal Growth Factor Receptor EGFRm Epidermal Growth Factor Receptor Mutant ESMO European Society For Medical Oncology IHC Immunohistochemistry IV Intravenous MET Mesenchymal Epithelial Transition NGS Next-Generation Sequencing NSCLC Non-Small Cell Lung Cancer NTRK Neurotrophic Tyrosine Receptor Kinase OS Overall Survival PCR Polymerase Chain Reaction PD-L1 Programmed...

Strengths and limitations The key strengths of this study were the use of multiple, state-of-the-art, machine learning approaches to develop a simple, parsimonious model based on a few routinely collected variables from the OAK trial6 and validation of the model using data from other trials.7–9 Five issues that affect the clinical applicability of this model are discussed below. First, the study population used to train the model is no longer frequent in routine clinical practice.